^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zeltherva (galinpepimut-S)

    i
    Company:
    3DMed, Ayala Pharma, Memorial Sloan-Kettering Cancer Center, SELLAS Life Sciences
    Drug class:
    Wilms tumor 1 inhibitor
    Related drugs:
    Apply
    Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (NCT03761914)
    Phase 1/2
    Sellas Life Sciences Group
    Completed
    Last update posted :
    11/19/2024
    Initiation :
    09/30/2019
    Primary completion :
    07/05/2022
    Completion :
    10/27/2022
    HER-2 • KRAS • PGR • WT1 • BRCA • MUC16
    |
    HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation
    |
    Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
    Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma (NCT04040231)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    07/24/2019
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    WT1
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    Study of 3D189 in Patients With Hematologic Malignancies (NCT05320809)
    Phase 1
    3D Medicines
    Active, not recruiting
    Last update posted :
    10/25/2023
    Initiation :
    08/01/2022
    Primary completion :
    05/01/2024
    Completion :
    12/01/2024
    WT1
    |
    WT1 expression • WT1 positive
    |
    Zeltherva (galinpepimut-S)
    A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    04/07/2023
    Initiation :
    04/01/2016
    Primary completion :
    04/06/2023
    Completion :
    04/06/2023
    WT1 • MUC16 • CTAG1B
    |
    WT1 expression • CTAG1B expression • WT1 positive
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S)
    WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation (NCT01827137)
    Phase N/A
    Sellas Life Sciences Group
    Unknown status
    Last update posted :
    01/10/2020
    Initiation :
    04/01/2013
    Primary completion :
    06/01/2018
    Completion :
    08/01/2020
    IFNG • WT1 • CD4
    |
    WT1 expression • WT1 positive
    |
    lenalidomide • bortezomib • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 (NCT01890980)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/10/2019
    Initiation :
    04/01/2013
    Primary completion :
    04/01/2020
    Completion :
    04/01/2021
    WT1 • CSF2
    |
    Zeltherva (galinpepimut-S)
    WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (NCT01266083)
    Phase 2
    Sellas Life Sciences Group
    Completed
    Last update posted :
    11/30/2018
    Initiation :
    12/01/2010
    Primary completion :
    02/01/2018
    Completion :
    02/01/2018
    FLT3 • NPM1 • WT1
    |
    NPM1 mutation
    |
    Zeltherva (galinpepimut-S)
    WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy (NCT01265433)
    Phase 2
    Sellas Life Sciences Group
    Completed
    Last update posted :
    11/05/2018
    Initiation :
    12/21/2010
    Primary completion :
    07/25/2017
    Completion :
    07/25/2017
    WT1 • CSF2
    |
    Zeltherva (galinpepimut-S)
    Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (NCT01842139)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    03/09/2018
    Initiation :
    12/05/2011
    Primary completion :
    02/02/2015
    Completion :
    03/01/2018
    CD8 • IFNG • WT1 • FOXP3
    |
    FOXP3 expression
    |
    Zeltherva (galinpepimut-S) • Hiltonol (poly-ICLC) • Simulect (basiliximab)
    Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma (NCT00398138)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    03/02/2016
    Initiation :
    10/01/2006
    Primary completion :
    06/01/2009
    Completion :
    06/01/2009
    WT1
    |
    Zeltherva (galinpepimut-S) • Leukine (sargramostim)